Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label Sofosbuvir/Velpatasvir/voxilaprevir(GS-9857). Show all posts
Showing posts with label Sofosbuvir/Velpatasvir/voxilaprevir(GS-9857). Show all posts
Saturday, July 15, 2017

Hepatitis C Genotype 3 - FDA Approved And Soon To Be Approved Therapies

›
September: Updated AASLD IDSA HCV Guidance This page was updated on Aug 3, 2017 to include AbbVie's FDA approval of MAVYRET™ (glecapre...
Wednesday, July 5, 2017

Sofosbuvir, Velpatasvir and Voxilaprevir combination for the treatment of hepatitis C- Review Article

›
Expert Rev Gastroenterol Hepatol. 2017 Jul 4. doi: 10.1080/17474124.2017.1351295. [Epub ahead of print] Sofosbuvir, Velpatasvir and Voxil...
Tuesday, July 4, 2017

Hepatitis C Therapies Perform Well in Challenging Patients

›
Medscape Coverage from Digestive Disease Week (DDW) 2017 Hepatitis C Therapies Perform Well in Challenging Patients William F. Balistr...
Friday, June 30, 2017

Pangenotypic regimens and the next generation hepatitis C virus therapy

›
The latest issue of Clinical Liver Disease Clinical Liver Disease (CLD) is a digital educational resource published on behalf of the Ameri...
Monday, June 26, 2017

HCV Treatment Options in 2017/2018: What’s Here and What’s Coming Soon

›
HCV Treatment Options in 2017/2018: What’s Here and What’s Coming Soon Clinical Care Options *Free registration required Greetings, h ...
Friday, June 23, 2017

Hepatitis C: AbbVies MAVIRET (glecaprevir/pibrentasvir) and Gilead’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) Receives CHMP Positive Opinion

›
AbbVies  MAVIRET (glecaprevir/pibrentasvir) and Gilead’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) Receives CHMP Positive Opinion Tw...
Wednesday, June 21, 2017

Investigational Hepatitis C Drugs Show Promising Results

›
Investigational Hepatitis C Drugs Show Promising Results By Barbara Jungwirth From TheBodyPRO.com June 20, 2017 Newer hepat...
Tuesday, June 13, 2017

Medscape - Early Look at Two New Hepatitis C Pangenotypic Therapies

›
Medscape Coverage from Digestive Disease Week (DDW) 2017 COMMENTARY Early Look at Two New Hepatitis C Pangenotypic Therapies Digestive ...
Thursday, June 1, 2017

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

›
New England Journal of Medicine Full Text PDF Download http://freepdfhosting.com/1fcc820940.pdf?platform=hootsuite Abstract Sofosb...
Monday, May 15, 2017

Emerging Therapies for Genotype 3 HCV

›
EASL 2017: Emerging Therapies for Genotype 3 HCV ...
Thursday, April 20, 2017

ILC 2017: SOF/VEL with or without VOX- High efficacy with investigational direct-acting antiviral treatment combination is accompanied with substantial gains in patient-reported outcomes

›
ILC 2017: High efficacy with investigational direct-acting antiviral treatment combination is accompanied with substantial gains in patient-...

International Liver Congress/Healio - Three HCV drugs may not be better than two

›
Expert: Three HCV drugs may not be better than two AMSTERDAM — The benefits of both double and triple direct-acting antiviral therapy combi...
Friday, March 17, 2017

In Case You Missed It - Review Gilead's HCV Investigational Regimen Sofosbuvir/Velpatasvir/Voxilaprevir

›
Review Sofosbuvir/Velpatasvir/Voxilaprevir It can be overwhelming trying to sift through research about newly approved or investigational...